Understanding Alzheimer's Disease

Alzheimer's dementia (AD) affects 6 million Europeans with 10% of people over age 65 and more than a quarter over 85. Given the steady aging of European societies, dementia and cognitive decline have developed into a major health problem with an enormous socioeconomic impact for patients, their...

Full description

Saved in:
Bibliographic Details
Other Authors: Zerr, Inga (Editor)
Format: Electronic Book Chapter
Language:English
Published: IntechOpen 2013
Subjects:
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_66435
005 20210420
003 oapen
006 m o d
007 cr|mn|---annan
008 20210420s2013 xx |||||o ||| 0|eng d
020 |a 46004 
020 |a 9789535110095 
020 |a 9789535171003 
040 |a oapen  |c oapen 
024 7 |a 10.5772/46004  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a MJN  |2 bicssc 
100 1 |a Zerr, Inga  |4 edt 
700 1 |a Zerr, Inga  |4 oth 
245 1 0 |a Understanding Alzheimer's Disease 
260 |b IntechOpen  |c 2013 
300 |a 1 electronic resource (496 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Alzheimer's dementia (AD) affects 6 million Europeans with 10% of people over age 65 and more than a quarter over 85. Given the steady aging of European societies, dementia and cognitive decline have developed into a major health problem with an enormous socioeconomic impact for patients, their families and caregivers, national health care systems, and society. Without any means to prevent or delay disease onset, the number of people with dementia is predicted to double by 2030 and triple by 2050. There is an urgent need for innovative strategies to increase understanding of pathological events that would translate into the development of successful prevention or, possibly, novel treatment strategies. Progresses in understanding pathological events in AD have been possible by using cell cultures, genetically modified organisms and animal models that lack the complexity of events occurring in humans. We need to overcome this limitation also by using data from humans - for studying pathological pathways in AD in a multidisciplinary setting. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/3.0/  |2 cc  |4 https://creativecommons.org/licenses/by/3.0/ 
546 |a English 
650 7 |a Neurology & clinical neurophysiology  |2 bicssc 
653 |a Neurology & clinical neurophysiology 
856 4 0 |a www.oapen.org  |u https://mts.intechopen.com/storage/books/3296/authors_book/authors_book.pdf  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/66435  |7 0  |z DOAB: description of the publication